Lymphokines, E.g., Interferons, Interlukins, Etc. Patents (Class 530/351)
  • Patent number: 11389507
    Abstract: Methods are provided for the prevention and/or treatment of pain, interstitial cystitis and/or overactive bladder in a subject using an IPSE protein, such as H03 H-IPSE, H06 H-IPSE, M-IPSE or other IPSE homologs, variants, mutants or mimics. The IPSE protein can be administered prior to, contemporaneously with, and/or after the subject develops pain, interstitial cystitis and/or overactive bladder. Pharmaceutical compositions also are provided that contain one or more IPSE proteins in a pharmaceutically acceptable carrier, excipient or diluent.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 19, 2022
    Assignee: BIOMEDICAL RESEARCH INSTITUTE
    Inventors: Michael Hsieh, Loc Huu Le, Evaristus Chibunna Mbanefo
  • Patent number: 11389508
    Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 19, 2022
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Dae Jin Kim, Jong Soo Lee, Young Jin Park, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
  • Patent number: 11390665
    Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: July 19, 2022
    Assignee: The Scripps Research Institute
    Inventors: Vaughn Smider, Omar A. Bazirgan, Hongyuan Helen Mao, Peter Schultz, Feng Wang, Yong Zhang
  • Patent number: 11377490
    Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond-linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 5, 2022
    Assignee: Sichuan Clover Biopharmaceuticals, Inc
    Inventor: Peng Liang
  • Patent number: 11365231
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: June 21, 2022
    Assignee: Altor BioScience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
  • Patent number: 11311032
    Abstract: The present invention provides a new wine yeast product in a frozen form. The product is produced in a fermenter, concentrated, cryoprotectants are added. This mixture is then frozen at ?50° C. What makes this product unique is that besides the fact that it is frozen, it can be directly added to grape juice as no rehydration is required because the yeast was not dehydrated in the production process.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 26, 2022
    Assignee: CHR. HANSEN A/S
    Inventors: Jan Hendrik Sweigers, Annicka Bunte, Sylvester Holt, Mansour Badaki
  • Patent number: 11242371
    Abstract: Disclosed are fusion polypeptides comprising fragments from a first and a second isoform of an interferon lambda family, nucleic acids encoding the fusion polypeptides, and vectors and host cells containing the same, and methods of making and using such compositions in treatment of interferon lambda-related diseases, disorders, and conditions.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 8, 2022
    Assignee: Prosit Sole Biotechnology (Beijing) Co, Ltd
    Inventors: Hongyu Liu, Mingzhi Zhao, Hetong Sun
  • Patent number: 11207383
    Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 28, 2021
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Dae Jin Kim, Jong Soo Lee, Young Jin Park, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
  • Patent number: 11160869
    Abstract: Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: November 2, 2021
    Assignee: Applied Molecular Transport Inc.
    Inventors: Derek Maclean, Randall J. Mrsny, Kevin Yin, Tahir Mahmood, Bittoo Kanwar, Sally Postlethwaite, Weijun Feng, Sean Dalziel, Hyojin Kim, Rajendra Tandale, Marvin Garovoy, John Koleng
  • Patent number: 11117945
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: September 14, 2021
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
  • Patent number: 11008374
    Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: May 18, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Nantes, Centre National de la Recherche Scientifique (CNRS), Université d'Angers
    Inventors: Yannick Jacques, Erwan Mortier, Agnes Quemener, Ariane Plet
  • Patent number: 10975158
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 13, 2021
    Assignee: The Regents of the University of California
    Inventor: Sherie L. Morrison
  • Patent number: 10947521
    Abstract: A process for producing recombinant trypsin from prokaryote host cells in high yield and high specific activity is described. In particular, a process for producing recombinant trypsin from E. coli is described.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 16, 2021
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Mark C. Sleevi, Jack Lile
  • Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Patent number: 10946070
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Patent number: 10927158
    Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: February 23, 2021
    Assignee: Cue Biopharma, Inc.
    Inventors: Ronald D. Seidel, III, Rodolfo Chaparro
  • Patent number: 10766924
    Abstract: To provide an affinity support in which a binding property of a ligand to a target substance is improved. The affinity support contains a solid phase support and a protein ligand, wherein the protein ligand is represented by formula (1): R—R1 (1) wherein R represents a linker binding to the solid phase support, which contains a polyproline, and R1 represents a protein showing an affinity to immunoglobulin, and the R is bound to a C terminal or an N terminal of an amino acid sequence in R1.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 8, 2020
    Assignees: JSR CORPORATION, JSR LIFE SCIENCES CORPORATION
    Inventors: Takashi Ichii, Satoshi Nakamura, Jun-ichi Yasuoka, Kaori Itaya, Tomonori Shiotani
  • Patent number: 10618949
    Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond-linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: April 14, 2020
    Inventor: Peng Liang
  • Patent number: 10596228
    Abstract: A novel IFN-?/? independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-?1, IFN-?2, IFN-?3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-? proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-?R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-?R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: March 24, 2020
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sergei V. Kotenko, Grant F. Gallagher
  • Patent number: 10487133
    Abstract: The invention provides methods for producing a protein in a cell free protein synthesis system such that the protein does not contain an asparagine (Asn or N) residue at serine (Ser or S) positions. Also provided are compositions and nucleic acid templates for use in the methods described herein.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 26, 2019
    Assignee: Sutro Biopharma, Inc.
    Inventor: Gang Yin
  • Patent number: 10385307
    Abstract: Apparatus and corresponding method for concentration and washing of live mammalian cells, for preparation of human cell therapy products. Optimized parameters for a temperature regulated, completely closed, fully disposable and scalable counterflow centrifugation separation system having integrated disposables designed for both the input cells and output cells are provided.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 20, 2019
    Assignee: LONZA WALKERSVILLE, INC.
    Inventors: Jon Rowley, Jacob Pattasseril, Lye Theng Lock
  • Patent number: 10358477
    Abstract: The present invention relates to the stimulation of the IL-15Rbeta/gamma signalling pathway, to thereby induce and/or stimulate the activation and/or proliferation of IL-15Rbeta/gamma-positive cells, such as NK and/or T cells. Appropriate compounds include compounds comprising at least one IL-15Rbeta/gamma binding entity, directly or indirectly linked by covalence to at least one polypeptide which contains the sushi domain of the extracellular region of an IL-15Ralpha.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: July 23, 2019
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Yannick Jacques, Ariane Plet, Erwan Mortier, Agnes Quemener, Patricia Vusio
  • Patent number: 10144774
    Abstract: The invention relates to a modified process for the purification of IgG, improving the yield of IgG per liter of starting material without compromising the quality of the product.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: December 4, 2018
    Assignee: CSL BEHRING AG
    Inventors: Ibrahim El Menyawi, Doreen Siegemund
  • Patent number: 9907832
    Abstract: A novel IFN-?/? independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated INF-?1, IFN-?2, IFN-?3, based inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-? proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-?R1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-?R1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: March 6, 2018
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sergei V. Kotenko, Grant F. Gallagher
  • Patent number: 9815879
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: November 14, 2017
    Assignee: Sandoz AG
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • Patent number: 9731011
    Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: August 15, 2017
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 9732135
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: August 15, 2017
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Patent number: 9726666
    Abstract: A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, indicate the presence or progression of inflammatory bowel disease. Similar methods for diagnosing irritable bowel syndrome are also described. Various companion therapeutic methods and useful binding reagents are also described.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: August 8, 2017
    Assignee: TLA Targeted Immunotherapies AB
    Inventors: Ola Winqvist, Graham Cotton
  • Patent number: 9714276
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: July 25, 2017
    Assignee: Amgen Inc.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Zeqi Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • Patent number: 9616091
    Abstract: The present invention provides methods for reducing, attenuating, diminishing, preventing or inhibiting pulmonary inflammation in an animal by orally administering a plasma fraction comprising at least 30% by weight IgG and 10% or less by weight IgA to said animal prior to or following exposure or challenge of the animal to an endotoxin.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: April 11, 2017
    Assignee: THE LAURIDSEN GROUP, INC.
    Inventors: Eric Weaver, Joy Campbell, Louis Russell, Miquel Moreto Pedragosa, Anna Perez-Bosque, Francisco Javier Polo Pozo, Joseph Crenshaw
  • Patent number: 9611297
    Abstract: Provided are novel peptides of Formula SEQ ID No. 1: J1CysX1X2X3X4X5X6ProX7ThrCysJ2J3(J4)s(J5)t;?? (SEQ ID No. 1) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are effective inhibitors of light chains to uromodulin.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 4, 2017
    Assignee: Thrasos Therapeutics Inc.
    Inventors: Roger Leger, Gilles Dube, Marie-Elaine Caruso, Jerome Rossert
  • Patent number: 9534013
    Abstract: The subject invention provides a method for purifying a target protein from a mixture comprising the target protein and contaminating protein, comprising the steps of exposing the mixture to an effective amount of a cationic surfactant such that the contaminating protein is preferentially precipitated and recovering the target protein. Proteins purified according to the method of the invention are also provided.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: January 3, 2017
    Assignee: Horizon Pharma Rheumatology LLC
    Inventors: Meir Fischer, Eliyahu Harosh
  • Patent number: 9415115
    Abstract: Novel compounds of the general formula: in which X represents a polymer, Q represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; each of R1 and R2 independently represents a hydrogen atom or a C1-4alkyl group; and either Z1 represents a protein or a peptide linked to CR2 via a nucleophilic moiety, and Z2 represents a molecule linked to CR2 via a nucleophilic moiety, or Z1 and Z2 together represent a single group derived from a protein or peptide linked to CR2 via two nucleophilic moieties.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: August 16, 2016
    Assignee: POLYTHERICS LIMITED
    Inventors: Antony Robert Godwin, Stephen James Brocchini
  • Patent number: 9359421
    Abstract: The invention relates to suppressors of endogenous human interferon-gamma (INF-?) applicable in treatment of diseases associated with impaired activity of endogenous IFN-?. The suppressors of the invention are useful in treating autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. The invention includes inactive analogues or variants of IFN-? having preserved affinity to the IFN-? receptor, genetically modified in the domain responsible for triggering the signal transduction pathway.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: June 7, 2016
    Assignee: TIGO GmbH
    Inventors: Ivan Ivanov, Genoveva Nacheva, Stefan Petrov, Hans-Guenther Grigoleit
  • Patent number: 9320792
    Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 26, 2016
    Assignee: Ablynx N.V.
    Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
  • Patent number: 9266937
    Abstract: Disclosed herein are novel proteins that have reduced binding to the interleukin-7 receptor, compositions containing such proteins, and methods of using the same.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: February 23, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Annette Khaled
  • Patent number: 9243042
    Abstract: It is an object to provide a protein having a dockerin, which is suited to production in yeasts and other eukaryotic microorganism in which sugar chain modification is predicted, and which provides excellent cohesin-dockerin binding ability, along with a use thereof. The present invention uses, as a protein for constructing a protein complex using a scaffolding protein having a type I cohesin from Clostridium thermocellum, a protein having a dockerin having at least one dockerin-specific sequence which is a dockerin-specific sequence associated with cohesin binding in type I dockerins from C. thermocellum, and which either has no intrinsic predicted N-type sugar chain modification site or has aspartic acid substituted for the asparagine of an intrinsic predicted N-type sugar chain modification site.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: January 26, 2016
    Assignee: KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO
    Inventors: Hiroaki Suzuki, Takao Imaeda, Katsunori Kohda
  • Patent number: 9234022
    Abstract: This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human inteferon like alpha 2b(HuIFN-?2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 12, 2016
    Assignee: Novagen Holding Corporation
    Inventors: Haitao Wang, Chunsheng Mao, Jizhi Li, Ling Wang, Yong Du, Longbin Liu, Jing Xu, Rui Zhang
  • Patent number: 9200058
    Abstract: The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (?) and IL-21. The composition containing the double antagonist to TNF-? and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: December 1, 2015
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, the Catholic University of Korea
    Inventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Sun-Ha Yoon, Ji Hyun Park, Eun Jung Song, Jong-Ho Lee, Min Ji Seo, Sun Jung Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
  • Patent number: 9150849
    Abstract: The invention provides methods and compositions for screening polypeptide libraries that include variants comprising unnatural amino acids. In addition, the invention provides vector packaging systems and methods for packaging a nucleic acid in a vector. Compositions of vectors produced by the methods and systems are also provided.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: October 6, 2015
    Assignee: The Scripps Research Institute
    Inventors: Chang Liu, Meng-Lin Tsao, Vaughn Smider, Peter G. Schultz
  • Patent number: 9133243
    Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity are described. In several embodiments, peptide antagonists simultaneously inhibit the activity of multiple ?c-cytokine family members.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: September 15, 2015
    Assignee: BIONIZ, LLC
    Inventors: Yutaka Tagaya, Nazli Azimi
  • Patent number: 9081017
    Abstract: This invention relates to the identification and characterization of specific cellular responses which are associated with tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 1 (TNFR2). Selective modulation of these tumor necrosis factor receptors (TNFRs) Selective modulations of these responses may be useful in the promotion or inhibition of cell growth, for example, in the treatment of disease conditions, including cardiovascular and kidney diseases. Therapeutic methods employed selective TNFR1 and TNFR2 modulators are provided, along with screening methods for the identification of selective TNFR1 and TNFR2 modulators useful in such methods.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: July 14, 2015
    Assignees: Cambridge Enterprise Limited, Yale University
    Inventors: John Bradley, Jordan Pober, Paul Clark, Wang Min, Martin Kluger
  • Patent number: 9067994
    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 30, 2015
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
  • Patent number: 9056896
    Abstract: An object of the present invention is to provide a method for removing even small viruses from a high concentration monoclonal antibody solution using a membrane, and thus for recovering the antibody within a short time at high yield in the form of a filtrate. The present invention provides a method for producing a preparation containing a monoclonal antibody, which comprises a step of removing viruses by filtering viruses in a monoclonal antibody solution using a virus-removing membrane, wherein (1) the monomer content of the monoclonal antibody accounts for 90% or more; (2) the monoclonal antibody concentration in the monoclonal antibody solution ranges from 20 mg/ml to 100 mg/ml; (3) the monoclonal antibody solution contains at least a basic amino acid; and (4) the parvovirus removal rate of the virus-removing membrane satisfies the following conditions: LRV (Log Reduction Value: logarithmic reduction value)?4.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: June 16, 2015
    Assignee: ASAHI KASEI MEDICAL CO., LTD.
    Inventors: Tomoko Hongo, Masayasu Komuro
  • Patent number: 9051369
    Abstract: The present invention relates generally to novel recombinant polypeptides having avian cytokine properties and to genetic sequences encoding same. More particularly, the present invention is directed to recombinant avian Type III interferon polypeptides, and genetic sequences encoding same, together with cellular expression systems and uses for same. Even more particularly, the present invention is directed to avian interferon-? (IFN-?) and functional derivatives, homologues and fragments thereof and to methods of use thereof. The molecules and cells of the present invention are useful in a wide range of applications including, but not limited to, providing a means for the treatment and prophylaxis of disease conditions, in particular avian disease conditions, or for use as an immune response modulator. Also provided are diagnostic means for screening for immune response and screening means for identifying modulators of IFN-? protein or nucleic acid functionality.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 9, 2015
    Assignees: Commonwealth Scientific and Industrial Research Organisation, Australian Poultry CRC
    Inventors: John William Lowenthal, Andrew Gerard D. Bean, Adam Joseph Karpala
  • Publication number: 20150147292
    Abstract: The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10/Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 28, 2015
    Applicant: Joslin Diabetes Center, Inc.
    Inventors: C. Ronald Kahn, Siegfried Ussar
  • Publication number: 20150147294
    Abstract: The present invention provides methods for increasing survival in a subject, and/or preserving bone marrow function, and/or promoting hematopoietic recovery or restoration. The methods include administering a dose of IL-12 to the subject following an acute exposure to non-therapeutic whole body ionizing radiation. Formulations and kits are also provided.
    Type: Application
    Filed: December 19, 2014
    Publication date: May 28, 2015
    Applicant: Neumedicines, Inc.
    Inventor: Lena A. Basile
  • Publication number: 20150139945
    Abstract: The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.
    Type: Application
    Filed: December 11, 2014
    Publication date: May 21, 2015
    Applicant: UNIVERSITY OF CONNECTICUT
    Inventors: Leo Lefrancois, Thomas A. Stoklasek
  • Patent number: 9034310
    Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: May 19, 2015
    Inventor: Stephen B. Cantrell
  • Publication number: 20150132257
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Application
    Filed: December 12, 2014
    Publication date: May 14, 2015
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han